由于不稳定性,尼日利亚禁止多剂量的阿特梅瑟/Lumefantrine,敦促转而采用更安全的替代品。 Nigeria bans multi-dose Artemether/Lumefantrine due to instability, urging switch to safer alternatives.

尼日利亚的药物监管者NAFDAC重申其2025年禁止多剂量阿特梅瑟/Lumefantrine干粉用于口服悬浮,指出与水混合后不稳定会降低效力。 Nigeria’s drug regulator NAFDAC has reaffirmed its 2025 ban on multi-dose Artemether/Lumefantrine dry powder for oral suspension, citing instability after mixing with water that reduces effectiveness. 这项禁令现已于2026年生效,禁止对该产品进行任何新的登记、更新或变更,并要求制造商转用更安全的分散片片或单剂量沙粒。 The ban, now in effect in 2026, prohibits all new registrations, renewals, or variations for the product and requires manufacturers to switch to safer dispersible tablets or single-dose sachets. NAFDAC警告这种过时的配方可能导致治疗失败、严重并发症或死亡。 NAFDAC warns the outdated formulation may cause treatment failure, severe complications, or death. 尽管有禁令,但一些版本仍在流通,促使加强执法和公开呼吁,以报告可疑的不合标准药品。 Despite the ban, some versions remain in circulation, prompting intensified enforcement and public appeals to report suspected substandard medicines.